Business
BioVie Announces the Appointment of a New Chief Medical Officer
Dr. Joseph M. Palumbo, Distinguished Pharma Industry Veteran, to Oversee Development Programs in Neurodegenerative and Liver Disease RENO, Nev., Nov. 01, 2021
About this update from Biovie Inc.
[{"type":"text","content":"Dr. Joseph M. Palumbo, Distinguished Pharma Industry Veteran, to Oversee Development Programs in Neurodegenerative and Liver Disease\nRENO, Nev., Nov. 01, 2021 (GLOBE NEWSWIRE) -- BioVie Inc. (Nasdaq: BIVI), a clinical-stage company developing innovative drug therapies for the treatment of liver disease and neurodegenerative disease - announced today the appointment of Joseph M. Palumbo, MD, LFAPA, MACPsych, as the Company’s new Chief Medical Officer. In this role Dr. Palumbo will oversee the Company’s clinical development and operations activities, including the advancement of NE3107, an oral small molecule, blood-brain permeable modulator of ERK and NFkB (e.g. TNF transcription) expected to modulate neuroinflammation and insulin resistance, while still facilitating the homeostatic function inherent to their mechanisms (e.g., insulin signaling and neuron growth and survival). He will also be responsible for the development of BIV201 (continuous infusion terlipressin), an active agent used in over 40 countries to treat complications of liver cirrhosis, that is not yet available in either the US or Japan. “Dr. Palumbo has had a distinguished career of leadership in the Global Pharma Industry as a scientist, inventor, clinician, and drug developer, having guided multiple new drug programs through to regulatory approval in the United States, Asia, and Europe,” said Cuong Do, CEO of BioVie. “Dr. Palumbo’s experience leading major neuroscience programs at leading pharma companies will enhance BioVie’s approach clinical trial design and operations, thereby enhancing the probability of success of our clinical programs. We are delighted to be welcoming him to the BioVie team.” “I am excited to join BioVie and the efforts to develop NE3107 to help Alzheimer’s and Parkinson’s patients. NE3107 acts upon what we believe to be the critical central switch point in the biochemical pathways modulating inflammation and homeostasis, thus making NE3107 ideally positioned as an investigational therapy targeted towards the amelioration of neuroinflammation and insulin resistance associated with AD and PD disease pathology,” said Dr. Palumbo. “I’m also excited about BIV201, which has the potential to help patients with refractory ascites, a condition with no approved therapeutic in the US and a 50% mortality rate.” Dr. Palumbo joins BioVie from Zyner...